After adjusting for age, sex, type of regimen, concomitant use of EGFR inhibitors, ICIs and bevacizumab, baseline arterial hypertension, ischemic heart disease, heart failure, chronic kidney disease, cerebrovascular disease, and epilepsy, the occurrence of early-onset toxicity was significantly associated with early treatment cessation, with an odds ratio (OR) of 1.53 [95% CI 1.30 to 1.80] in a multiple variable logistic regression model (p < 0.001). Here, EGFR is linked to chronic kidney disease.